Background – sarcomatoid lung cancer (SLC)
• Comprises one percent of all lung malignancies.
• NSCLC with sarcoma-like differentiation or component of sarcoma.
• Five types per WHO: carcinosarcoma, giant cell, pleomorphic, pulmonary blastoma, spindle cell.
• NSCLC regimens and not sarcoma regimens (e.g. doxorubicin, ifosfamide) are typically utilized.
• Still, prognosis remains dismal. The purpose of this study, then, is to identify novel potential